Inflammatory Phenotypes Predict Changes in Arterial Stiffness Following Antiretroviral Therapy Initiation by Kelly, Christine et al.
 © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of 
America. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
Inflammatory Phenotypes Predict Changes in Arterial 
Stiffness following ART Initiation 
Christine Kelly
1,2,3
, Willard Tinago
1
, Dagmar Alber
4
, Patricia Hunter
4
, Natasha Luckhurst
5
, Jake 
Connolly
5
, Francesca Arrigoni
5
, Alejandro Garcia Abner
1
, Ralph Kamngona
2
, Irene Sheha
2
, Mishek 
Chammudzi
2
, Kondwani Jambo
2,6,7
, Jane Mallewa
6
, Alicja Rapala
8
, Robert S Heyderman
4
, Patrick 
WG Mallon
1
, Henry Mwandumba
2,6,7
, A. Sarah Walker
9
, Nigel Klein
4
,
 
Saye Khoo
3
.  
1.
Cente for Experimental Pathogen Host Research (CEPHR), University College Dublin, Ireland 
2.
Malawi 
Liverpool Wellcome Trust Clinical Research Program, Blantyre, Malawi 
3.
Institute of Translational Medicine, 
University of Liverpool, UK 
4.
Institute of Child Health, University College London, UK 
5.
Kingston University, 
Kingston, UK 
6.
College of Medicine, University of Malawi, Malawi 
7
Liverpool School of Tropical Medicine, 
Liverpool, UK.  
8.
Institute of Cardiovascular Science, University College London, UK 
9.
MRC Clinical Trials 
Unit, University College London, UK 
 
Corresponding author: Dr. Christine Kelly. Nelson Street, Dublin 7, Ireland.  
T +353 1 7164552, christine.kelly@ucd.ie 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa186/5760863 by guest on 01 M
arch 2020
 2 
 
Summary: Adults starting ART with advanced immunosuppression can be phenotyped into three 
inflammatory clusters. One cluster was defined by high T-cell PD1 expression and another by a 
hyper-inflamed biological profile. Changes in arterial stiffness on ART varied according to 
inflammatory phenotype. 
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Abstract  
Background: Inflammation drives vascular dysfunction in HIV, but in low-income settings causes of 
inflammation are multiple, and include infectious and environmental factors. We hypothesised that 
patients with advanced immunosuppression could be stratified into inflammatory phenotypes that 
predicted changes in vascular dysfunction on ART. 
Methods: We recruited Malawian adults with CD4<100 cells/ul two weeks after starting ART in the 
REALITY trial (NCT01825031). Carotid femoral pulse wave velocity (cfPWV) measured arterial 
stiffness 2, 12, 24 and 42 weeks post-ART initiation. Plasma inflammation markers were measured by 
electrochemiluminescence at weeks 2 and 42. Hierarchical clustering on principal components 
identified inflammatory clusters.  
Results: 211 HIV-positive participants grouped into three clusters of inflammatory marker profiles 
representing 51 (24%) (cluster-1), 153 (73%) (cluster-2) and 7 (3%) (cluster-3) individuals. Cluster-1 
showed markedly higher CD4 and CD8 T-cell expression of HLADR and PD1 vs cluster-2 and 
cluster-3 (all p<0.0001). Although small, individuals in cluster-3 had significantly higher levels of 
cytokines reflecting inflammation (IL6, IFNɣ, IP10, IL1RA, IL10), chemotaxis (IL8), systemic and 
vascular inflammation (CRP, ICAM1, VCAM1) and SAA (all p<0.001). In mixed-effects models, 
cfPWV changes over time were similar for cluster-2 vs cluster-1 (relative-fold-change 0.99 (95% CI 
0.86-1.14, p=0.91, but greater in cluster-3 vs cluster-1 (relative-fold-change 1.45 (95% CI 1.01-2.09, 
p=0.045).  
Conclusions: Two inflammatory clusters were identified: one defined by high T-cell PD1 expression 
and another by a hyper-inflamed profile and increases in cfPWV on ART. Further clinical 
characterisation of these inflammatory phenotypes could help target vascular dysfunction 
interventions to those at highest risk. 
Keywords: Inflammatory phenotype, Arterial stiffness, Sub-Saharan Africa 
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Introduction  
Chronic inflammation persists in people living with HIV (PLWH) despite long-term suppressive 
antiretroviral therapy (ART), contributing to vascular dysfunction and non-communicable diseases [1-
3]. Low income sub-Saharan Africa (SSA) faces an epidemiological transition in cardiovascular 
disease (CVD), as urbanisation increases traditional cardiovascular risk factors [4, 5]. Hypertension is 
already highly prevalent; diabetes, dyslipidaemia and obesity are increasing [6-8]. Already, 80% of 
haemorrhagic strokes in people under 65 years occur in low and middle income countries [9]. 
Continued increases in non-communicable disease in low-income SSA are of major public health 
concern and the focus of sustainable development goal 3.4 [9, 10]. Life expectancy is increasing 
amongst PLWH in the region and the effects of  persistent chronic inflammation superimposed upon 
an evolving background of cardiovascular risk in an ageing cohort are unknown [11, 12]. 
In high-income settings, drivers such as microbial translocation, persistent HIV replication and latent 
co-infections have been implicated in chronic inflammation [13-15]. Precise pathways remain unclear, 
with some individuals being affected more than others, and become even more complex in low-
income settings where additional drivers of inflammation are multiple. Recurrent acute or sub-acute 
infections such as TB, CMV, malaria, helminths and invasive bacterial disease underpin an exhausted 
immune system [16-18]. Cotrimoxazole decreases immune activation, suggesting that modifying 
infection-related drivers may help reduce chronic inflammation [19]. Late presentation with low CD4 
is still common in SSA, and is associated with lymph node fibrosis and poor immune reconstitution 
on ART [20-22]. Immune activation has also been linked to poor ART adherence [23], food insecurity 
[24] and host genetics [25] in SSA cohorts.  
A pragmatic approach to this complex process might be to identify common inflammatory phenotypes 
that identify those at highest risk from the complications of chronic inflammation, and hence target 
limited resources for risk reduction. This approach has been used successfully to guide treatment in 
other diseases characterised by chronic inflammation, such as asthma and systemic lupus 
erythamatosus (SLE) [26, 27].  
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Arterial stiffness has been used as a measure of vascular dysfunction in HIV studies as well as other 
chronic inflammatory conditions [28-33]. cfPWV is a gold standard measurement of arterial stiffness 
and has been validated as a physiological biomarker of cardiovascular events and mortality [29, 30]. 
We have previously shown that arterial stiffness, as measured by carotid femoral pulse wave velocity 
(cfPWV), is increased in PLWH during the first 3 months of ART and in people experiencing 
unstructured treatment interruptions [3, 15].  
We aimed to investigate whether PLWH starting ART with advanced immune suppression could be 
stratified into inflammatory phenotypes, and whether these phenotypes predicted changes in arterial 
stiffness following ART initiation. 
Methods 
ART-naïve adults with a new HIV diagnosis and CD4 <100 cells/uL were recruited prospectively 
from the ART clinic and voluntary HIV testing clinic at Queen Elizabeth Central Hospital, Blantyre, 
Malawi, along with HIV negative adults with no evidence of infection within the previous 3 months 
(full details of recruitment in [3]; most HIV-positive patients were recruited from the REALITY trial 
[NCT01825031]). In brief, participants underwent a detailed clinical assessment and blood draw for 
plasma storage at 2 (enrolment) and 42 weeks post ART initiation. The enrolment visit for HIV-
positive participants was 2 weeks after ART initiation to minimise visit burden in this unwell group. 
cfPWV was assessed on all participants at enrolment, and 10, 22 and 40 weeks later. All participants 
provided informed written consent and ethical approval was granted by the College of Medicine 
Research and Ethics Committee (COMREC), University of Malawi (P.09/13/1464) and the University 
of Liverpool Research and Ethics Committee (UoL000996).  
Surface immunophenotyping of T-cells was performed on fresh PBMCs using flow cytometry as 
previously described [3]. T-cell activation, exhaustion and senescence was defined as CD38/HLADR, 
PD1 and CD57 expression, respectively. Monocytes were defined as classical (CD14
++
CD16
-
), 
intermediate (CD14
++
CD16
+
) or nonclassical (CD14
+
CD16
+
). Stored plasma was tested for 22 
cytokines: Proinflammatory Panel-1 (IFN-, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL12p70, IL-13, 
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TNF-), Vascular Injury Panel-2 (SAA, CRP, VCAM-1, ICAM-1), Chemokine Panel-1 (MIP-1, IP-
10, MCP-1), Angiogenesis -Panel-1 (VEGF-A, bFGF) and single analyte assays for IL1R antagonist 
and IL-7, all from Meso Scale Discovery (MSD, Rockland, MD, USA). Assays were performed 
following the manufacturer’s instructions and recommended dilutions for human plasma. Soluble 
CD163 was measured in plasma diluted at 1:20 using DuoSet antibodies (R&D Systems, Minneapolis, 
MN, USA) on MSD Multiarray plates. CMV viral loads were quantified by DNA PCR in a subset of 
participants with available plasma as described previously[34]. A negative CMV PCR was defined as 
<100 copies/mL and corresponded with values less than 3 cycle thresholds above background 
fluorescence. 
Statistical analysis 
Categorical and continuous variables were compared using chi-squared and Kruskal-Wallis or 
Wilcoxon ranksum tests, respectively. We used principal component analysis (PCA) to reduce the 
dimensionality/eliminating redundancy across all 22 biomarkers., Briefly, PCA enables reduction of a 
larger number of variables into a smaller number of summary components, while still retaining as 
much of the variance in the original variables as possible. Prior to PCA, the biomarkers were log-
transformed (for approximate normality) and scaled to ensure biomarkers with larger intrinsic 
variation did not dominate the PCA. Unsupervised hierarchical clustering was then performed on 
the principal components (PCs), using Ward’s minimum variance method and squared Euclidean 
distance as the distance measure, and determining the optimal number of clusters using the Silhouette 
method [35]. For PCA, we used a single imputation for absolute values of missing biomarker data 
(ranging from 0.5-20%) for patients with any biomarker values using the SVDImpute algorithm 
(which imputes based on eigenvectors, analogous to PCA) within the R impute package [36].  
We used logistic regression to investigate predictors of CMV positivity adjusting for clinical risk 
factors, using multivariable fractional polynomials to account for non-linear effects of biomarkers. 
We then examined the association between changes in cfPWV (log10 transformed for normality) over 
time and inflammatory clusters using linear mixed models with patient-specific random intercepts. 
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We adjusted the model for baseline cfPWV values, confounders (age and sex) and mediators (blood 
pressure and haemoglobin) as previously identified [3].  
Analysis was undertaken using Stata 13.1 (Statacorp, College Station, USA) and R V3.5.1 (The R 
Foundation for Statistical Computing, Vienna, Austria).  
Results 
In total 279 HIV-positive participants were enrolled. The median age was 36 years (IQR 31–43), nadir 
CD4 count 41 cells/µL (18-62) and HIV viral load 110,000 copies/mL (4000–290,000). The 
median(IQR) blood pressure was 120/73mmHg (108/68-128/80) and total cholesterol 3.6 mmol/L 
(3.0–4.4). 110 HIV-negative participants had comparable age and blood pressure (median[IQR] 35 
years [31–41] and 128/75mmHg [114/68–134/82]). All but one HIV patient received first line ART of 
tenofovir-lamivudine-efavirenz, with the exception receiving zidovudine-lamivudine-nevirapine. 45 
(16%) HIV-positive participants were diagnosed with an acute co-infection at study enrolment, 
including 30 with TB, 4 with cryptococcal meningitis and 4 with malaria. CMV PCR was positive for 
61 (32%) of 193 tested HIV-positive and 1 (2%) of 59 HIV-negative participants at enrolment, with 
median(IQR) CMV viral load 928 copies/mL (412–3052) in those positive. CMV PCR became 
undetectable for all except one HIV-positive participant after 42 weeks of ART. The median(IQR) 
cfPWV for the HIV-positive participants was 7.3 m/s (6.5–8.2).  
15 participants died. Of 14 PLWH who died, five were due to TB, three cryptococcal meningitis, one 
pneumonia, one Kaposi sarcoma, one gastroenteritis and three of unknown cause. One HIV-negative 
participant died from a cerebrovascular accident on a background of hypertension and obesity.  
Inflammatory biomarkers 
Inflammatory biomarker data was available for 211 (76%) HIV-positive and 62 (56%) HIV-negative 
participants. At enrolment, almost all markers were significantly elevated in those with HIV compared 
to those without, particularly anti-inflammatory cytokines (IL10 and IL1Ra: 2.9 and 1.9 fold higher); 
T-cell activation (IFNɣ and IL7: 2.3 and 4.9 fold higher); and angiogenesis (bFGF and VEGF: 4.9 and 
2.6 fold higher) (Supplementary Table 1). All inflammatory biomarkers except IL13 decreased in 
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HIV-positive participants during the following 42 weeks on ART. However levels of TNFα, IL7, 
MCP1, IP10, VEGF, bFGF, ICAM and CRP remained significantly elevated compared to HIV-
negative patients at the final study visit (all p<0.001, Supplementary Table 2).  
Whilst many cytokines were univariably associated with CMV positivity, only associations with 
VCAM and MIP1β, and baseline CD4, persisted in multivariable models after adjustment for age and 
sex (p=0.04 and 0.01 respectively, Supplementary Table 3).  
Amongst HIV-positive participants, individual biomarkers were not associated with cfPWV at 
enrolment on univariate analysis (p>0.05), with the exception of IL13 (spearman rho -0.21, p=0.01, 
Supplementary Table 4).  
Characterisation of immune phenotypes during ART initiation 
Unsupervised hierarchical clustering of the 22 inflammatory biomarkers was performed for the 211 
HIV-positive participants with any biomarker data. Three clusters were identified representing 51 
(24%) (cluster-1), 153 (73%) (cluster-2) and 7 (3%) (cluster-3) participants (Figure 1). Figure 2 and 
Supplementary Table 5 compare the inflammatory biomarkers across clusters.  
Although cluster-3 was small, participants had markedly increased pro-inflammatory cytokines 
compared to cluster-1 and cluster-2. Concentrations of IL6, CRP and IFNɣ were between 10 and 50 
fold higher (all p<0.0001, Supplementary Table 5) and levels of serum amyloid was over 100 fold 
higher (p=0.0003). For participants in cluster-1, CRP and serum amyloid were increased compared to 
cluster-2 (both p=0.02) but to a lesser extent than the levels seen in cluster-3 (Supplementary Table 
5).  
Table 1 shows clinical characteristics and cell surface immune activation markers of patients in each 
cluster, and supplementary Table 6 shows the relevant characteristics for those without available 
biomarker data. There was no evidence of differences in age, blood pressure, diagnosis of acute co-
infection or CMV positivity between clusters (p=0.77, 0.47, 0.72 and 0.90, respectively). There was a 
trend towards lower nadir CD4 count in cluster-3 compared to cluster-2 [CD4 17 cellscells/µL (11–
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44) versus 41 (19–63), p=0.08], but no evidence of overall difference across the three groups 
(p=0.44). 
Participants in cluster-1 were characterised by higher proportions of PD-1 expressing CD4 and CD8 
T-cells compared to cluster-2 and cluster-3 [Table 1, CD4: median 69% versus 39% and 33%, 
respectively; CD8: 54% versus 33% and 42%, respectively, both p<0.0001] as well as a lower 
proportion of intermediate monocytes [7.7 versus 10.3 versus 12.8 respectively, p=0.004]. Lower 
proportions of activated CD4 and CD8 T-cells were found in cluster-2 [CD4: 68% versus 86% in 
cluster-1 and 69% in cluster-3; CD8: 72% versus 84% vs 83% respectively, p<0.0001]. However, all 
14 deaths in HIV-positive participants were in cluster-2 (p=0.097).  
Relationship between Immune phenotype at ART initiation and arterial stiffness  
Median (IQR) cfPWV at baseline for clusters 1, 2 and 3 was 7.5m/s (7.4–7.6), 7.3m/s (7.2–7.4) and 
6.6m/s (6.3–6.8) respectively (p=0.04). When adjusted for a priori identified confounders and 
mediators in multivariate analysis, baseline cfPWV was lower in cluster-2 and cluster-3 compared to 
cluster-1 [cluster-2: fold change -9% (95% CI -17% to 1%), p=0.08; cluster-3: fold change -17% 
(95% CI -53% to -15%), p=0.002, Table 2]. The effect of inflammatory cluster on baseline cfPWV 
was not attenuated when CMV positivity was added to this model [cluster-2: fold change -10% (95% 
CI -19% to 0%), p=0.04; cluster-3: fold change -37% (95% CI -56% to -11%), p=0.008].  
Between week 2 and week 42, change in cfPWV for clusters 1, 2 and 3 was -0.5m/s (95% CI -1.0 to 
+0.1), -0.4m/s (95% CI -1.0 to +0.2) and +0.1m/s (95% CI -0.6 to +1.7) respectively (Figure 3). 
Mixed effects models were constructed to assess the effect of inflammatory biomarker cluster on 
cfPWV slope over 42 weeks when adjusted for a priori identified confounders and mediators (Table 
3). Compared with the rate of change in cluster-1, fold change for cluster-2 was 0.99 (95% CI 0.86 to 
1.14, p=0.91) and for cluster-3 was 1.45 (95% CI 1.01 to 2.09, p=0.045).  
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Discussion 
Patients living with HIV infection and presenting with advanced immune suppression can be 
classified according to distinct inflammatory phenotypes. We identified two inflammatory 
phenotypes: one characterised by T-cell activation and, in particular, high levels of PD-1 expression, 
and another smaller subgroup with markedly elevated inflammatory cytokines and a higher proportion 
of intermediate monocytes. These phenotypes tended to experience less favourable trends in arterial 
stiffness on ART compared to the third phenotype which had decreased T-cell activation and 
decreased cfPWV on ART. 
Three pathways in particular were of interest in cluster-3. Biomarkers of angiogenesis, bFGF and 
VEGF have previously been linked to aberrant fibrosis, a possible mechanism for the development of 
non-communicable complications on ART [37]. High IFNɣ and IL7 levels indicate a role for 
lymphocyte recruitment in this cluster. This is consistent with recent data showing production of IFNɣ 
from cytotoxic T lymphocytes in HIV infection occurs due to delayed killing of resistant HIV-
infected macrophages, which potentiate the inflammation cycle [38]. Anti-inflammatory cytokines 
were also upregulated in this cluster, with high levels of IL10 and IL1Ra. However, all deaths - which 
were predominantly due to infections - were in cluster-2 (the largest subgroup) where relatively lower 
levels of inflammation were seen. Taken together, we could hypothesise a survival benefit for those 
able to produce and regulate a more marked inflammatory response [39], with endothelial damage the 
cost in the longer term.  
In contrast, cluster-1 was not defined by marked increases in inflammatory biomarkers, but was 
associated with higher proportions of activated T-cells, especially those expressing PD-1. PD-1 
expressing T-cells have been previously shown to be independently associated with changes in 
cfPWV in this cohort [3]. Given that cell surface markers were not added to the cluster model (only 
the plasma biomarker data), this finding is interesting and the inflammatory biomarker signature 
warrants further investigation. We did not find any evidence that CMV viraemia explains 
inflammation related arterial stiffness in this cluster, although it was associated with plasma markers 
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of endothelial damage overall. However, our sample size was not large enough to detect a small effect 
of CMV on arterial stiffness. 
Few studies to date have specifically dealt with inflammation in people with CD4 <100cells/µL who 
are commencing ART. As well as a low CD4 count predisposing to co-infections which may trigger 
inflammation, the inflammatory response itself might potentiate CD4 T-cell loss. Shive and 
colleagues previously demonstrated that pro-inflammatory cytokines driving CD4 T-cell cycling led 
to increased cell turnover and diminished responsiveness to IL7 [40]. As more patients presenting 
with low CD4 counts survive past the initial few months of ART, characterising inflammatory 
phenotypes at ART initiation may provide insights into the heterogeneity of chronic inflammation in 
the longer term [41, 42] and identify potential areas for intervention. 
Previous studies from SSA have investigated the relationship between inflammation and vascular 
dysfunction. In a South African cohort, markers of endothelial damage including VCAM and ICAM 
were raised in people with HIV compared to negative controls and levels of VCAM were associated 
with CD4 count [43]. Siedner and colleagues demonstrated that changes in sCD14 and IL6 during the 
first 6 months of ART predicted a lower carotid intima thickness measurements after 7 years of ART 
[44]. Decreases in CRP and TNFα correlated with improvements in vascular function in a small 
cohort of malnourished patients in Southern Africa. Our data adds to current knowledge, suggesting 
that inflammatory phenotype at ART initiation may determine different trajectories of vascular 
function over time.  
Sherzer and colleagues investigated cross sectional biomarker clustering for patients with HIV on 
ART in USA, in the context of cardiac failure [45]. Using a panel of 8 inflammatory and heart failure 
markers, they identified three clusters, one of which was also a pro-inflammatory phenotype and was 
associated with higher mortality. Banchereau and colleagues used inflammatory biomarkers and 
transcriptomics to stratify SLE phenotypes according to underlying mechanistic pathways and identify 
clinically applicable biomarkers and treatments for each group [26]. 
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Study strengths include plasma biomarker data in a large, well clinically characterised cohort of 
patients with HIV infection, recruited close to ART initiation. Previous studies have concentrated on 
cross-sectional analysis; here we assessed changes in plasma biomarkers, cell surface markers and 
arterial stiffness during the first 42 weeks of ART. In addition, we also included a HIV-negative 
cohort for comparison at both time points.  
Limitations include the fact that the number of participants in cluster-3 was very small, restricting 
inference about their characteristics. However, these patients may represent those at highest risk of 
inflammation driven complications of HIV and those most likely to benefit from targeted 
interventions. Although we did not find any differences that suggest this group of patients were 
experiencing greater rates of acute co-infection or sepsis, this remains a possibility given the low 
numbers. However, cfPWV remained lower in this group than the rest of the cohort even at week 10, 
making it unlikely that sepsis alone was an explanation for the lower arterial stiffness observed at 
enrolment.  
Our cohort had advanced immune suppression with CD4 <100 cells/µL at ART initiation, restricting 
generalisabilty to the HIV population as a whole. Indeed inflammatory phenotypes may differ 
depending on HIV stage, as well as treatment status, and further work will be needed for those with 
higher CD4 counts and those established on ART. Although arterial stiffness represents one 
mechanism through which clinical cardiovascular disease may occur, large clinically validated studies 
will also be required in the future.  
Reproducible inflammatory phenotypes could inform clinical trials seeking to reverse chronic 
inflammation. To date, trials in this area of interventions such as statins, valganciclovir, dietary 
supplements, metformin and anti-inflammatory immunomodulatory agents have shown only modest 
effects [46-50]. One possibility is that the effects of interventions may have been limited by the 
heterogeneity of the patient populations, and would be enhanced when targeted towards a particular 
inflammatory phenotype.  
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This study identifies potential clinically relevant inflammatory phenotypes in people living with HIV. 
In addition, we present novel data on the possible association between inflammatory phenotypes and 
change in vascular dysfunction on ART. Further elucidation of the clinical implications as well as 
drivers of inflammatory phenotypes might help identify therapeutic targets to modulate inflammation 
driven cardiovascular disease in people living with HIV.  
 
Acknowledgements 
We acknowledge the patients and their families as well as the staff in the ART clinic and Department 
of Medicine at Queen Elizabeth Central Hospital, Blantyre, Malawi.  
We thank the REALITY trial group for their support with study design and implementation. 
The REALITY trial group consists of: 
Participating Centres: Joint Clinical Research Centre (JCRC), Kampala, Uganda (coordinating centre 
for Uganda): P Mugyenyi, C Kityo, V Musiime, P Wavamunno, E Nambi, P Ocitti, M Ndigendawani. 
JCRC, Fort Portal, Uganda: S Kabahenda, M Kemigisa, J Acen, D Olebo, G Mpamize, A Amone, D 
Okweny, A Mbonye, F Nambaziira, A Rweyora, M Kangah and V Kabaswahili. JCRC, Gulu, 
Uganda: J Abach, G Abongomera, J Omongin, I Aciro, A Philliam, B Arach, E Ocung, G Amone, P 
Miles, C Adong, C Tumsuiime, P Kidega, B Otto, F Apio. JCRC, Mbale, Uganda: K Baleeta, A 
Mukuye, M Abwola, F Ssennono, D Baliruno, S Tuhirwe, R Namisi, F Kigongo, D Kikyonkyo, F 
Mushahara, D Okweny, J Tusiime, A Musiime, A Nankya, D Atwongyeire, S Sirikye, S Mula, N 
Noowe. JCRC, Mbarara, Uganda: A Lugemwa, M Kasozi, S Mwebe, L Atwine, T Senkindu, T 
Natuhurira, C Katemba, E Ninsiima, M Acaku J Kyomuhangi, R Ankunda, D Tukwasibwe, L 
Ayesiga. University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe: J Hakim, K Nathoo, 
M Bwakura-Dangarembizi, A Reid, E Chidziva, T Mhute, GC Tinago, J Bhiri, S Mudzingwa, M 
Phiri, J Steamer, R Nhema, C Warambwa, G Musoro, S Mutsai, B Nemasango, C Moyo, S Chitongo, 
K Rashirai, S Vhembo, B Mlambo, S Nkomani, B Ndemera, M Willard, C Berejena, Y Musodza, P 
Matiza, B Mudenge, V Guti. KEMRI Wellcome Trust Research Programme, Kilifi, Kenya: A Etyang, 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa186/5760863 by guest on 01 M
arch 2020
 14 
 
C Agutu, J Berkley, K Maitland, P Njuguna, S Mwaringa, T Etyang, K Awuondo, S Wale, J 
Shangala, J Kithunga, S Mwarumba, S Said Maitha, R Mutai, M Lozi Lewa, G Mwambingu, A 
Mwanzu, C Kalama, H Latham, J Shikuku, A Fondo, A Njogu, C Khadenge, B Mwakisha. Moi 
University Clinical Research Centre, Eldoret, Kenya: A Siika, K Wools-Kaloustian, W Nyandiko, P 
Cheruiyot, A Sudoi, S Wachira, B Meli, M Karoney, A Nzioka, M Tanui, M Mokaya, W Ekiru, C 
Mboya, D Mwimali, C Mengich, J Choge, W Injera, K Njenga, S Cherutich, M Anyango Orido, G 
Omondi Lwande, P Rutto, A Mudogo, I Kutto, A Shali, L Jaika, H Jerotich, M Pierre. Department of 
Medicine and Malawi-Liverpool Wellcome Trust Clinical Research Programme, College of Medicine, 
Blantyre, Malawi: J Mallewa, S Kaunda, J Van Oosterhout, B O'Hare, R Heyderman, C Gonzalez, N 
Dzabala, C Kelly, B Denis, G Selemani, L Nyondo Mipando, E Chirwa, P Banda, L Mvula, H Msuku, 
M Ziwoya, Y Manda, S Nicholas, C Masesa, T Mwalukomo, L Makhaza, I Sheha, J Bwanali, M 
Limbuni. Trial Coordination and Oversight: MRC Clinical Trials Unit at UCL, London, UK: D Gibb, 
M Thomason, AS Walker, S Pett, A Szubert, A Griffiths, H Wilkes, C Rajapakse, M Spyer, A 
Prendergast, N Klein. Data Management Systems: M Rauchenberger, N Van Looy, E Little, K 
Fairbrother. Social Science Group: F Cowan, J Seeley, S Bernays, R Kawuma, Z Mupambireyi. 
Independent REALITY Trial Monitors: F Kyomuhendo, S Nakalanzi, J Peshu, S Ndaa, J Chabuka, N 
Mkandawire, L Matandika, C Kapuya. Trial Steering Committee: I Weller (Chair), E Malianga, C 
Mwansambo, F Miiro, P Elyanu, E Bukusi, E Katabira, O Mugurungi, D Gibb, J Hakim, A Etyang, P 
Mugyenyi, J Mallewa. Data Monitoring Committee: T Peto (Chair), P Musoke, J Matenga, S Phiri.  
Endpoint Review Committee (independent members): H Lyall (Co-Chair), V Johnston (Co-Chair), F 
Fitzgerald, F Post, F Ssali, A Prendergast, A Arenas-Pinto, A Turkova, A Bamford. 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa186/5760863 by guest on 01 M
arch 2020
 15 
 
Funding 
This work was supported by a Wellcome Trust Clinical PhD Training Fellowship [grant number 
099934/Z/12/A], a strategic award from the Wellcome Trust for the MLW Clinical Research 
Programme and core support to the MRC Clinical Trials Unit at UCL [MC_UU_12023/23] 
[MC_UU_12023/26] and Joint Global Health Trials (UK Medical Research Council, Wellcome Trust, 
Department for International Development). The Meso Scale Discovery assays were funded by 
Merck, Sharp and Dohme. Cipla Ltd, Gilead Sciences, ViiV Healthcare/GlaxoSmithKline, Merck 
Sharp & Dohme donated drugs for REALITY. ASW is an NIHR Senior Investigator and reports 
money paid to institution from Gilead Sciences, and personal fees from Janssen outside the submitted 
work. WT has received support from the European Union’s Horizon 2020 Research and Innovation 
Programme under the Marie Sklodowska-Curie [grant No 666010]. S.K. reports grants and personal 
fees from ViiV Healthcare, grants from Gilead Sciences, and grants from Merck, outside the 
submitted work.  
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa186/5760863 by guest on 01 M
arch 2020
 16 
 
The authors have no conflicts of interest to declare. 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa186/5760863 by guest on 01 M
arch 2020
 17 
 
References 
1. Peterson TE, Baker JV. Assessing inflammation and its role in comorbidities among persons 
living with HIV. Current opinion in infectious diseases 2019; 32(1): 8-15. 
2. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and 
mortality in patients with HIV infection. PLoS Medicine 2008; 5(10): e203. 
3. Kelly C, Mwandumba HC, Heyderman RS, et al. HIV-related arterial stiffness in Malawian 
adults is associated with proportion of PD-1 expressing CD8 T-cells and reverses with anti-
retroviral therapy. J Infect Dis 2019. 
4. Cappuccio FP. Commentary: epidemiological transition, migration, and cardiovascular 
disease. Int J Epidemiol 2004; 33(2): 387-8. 
5. Amberbir A, Banda V, Singano V, et al. Effect of cardio-metabolic risk factors on all-cause 
mortality among HIV patients on antiretroviral therapy in Malawi: A prospective cohort 
study. PLoS One 2019; 14(1): e0210629. 
6. WHO. Report on the status of major health risk factors for noncommunicable diseases: WHO 
Africa Region, 2015. https://www.afro.who.int/sites/default/files/2017-06/15264_who_afr-
situation-ncds-15-12-2016-for-web_0.pdf, 2015. 
7. Manne-Goehler J, Geldsetzer P, Agoudavi K, et al. Health system performance for people 
with diabetes in 28 low- and middle-income countries: A cross-sectional study of nationally 
representative surveys. PLoS Medicine 2019; 16(3): e1002751. 
8. Noubiap JJ, Bigna JJ, Nansseu JR, et al. Prevalence of dyslipidaemia among adults in Africa: 
a systematic review and meta-analysis. (2214-109X (Electronic)). 
9. Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first-
ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden 
of Disease Study 2010. The Lancet Global health 2013; 1(5): e259-81. 
10. Bennett J. NCD Countdown 2030: worldwide trends in non-communicable disease mortality 
and progress towards Sustainable Development Goal target 3.4. Lancet 2018; 392(10152): 
1072-88. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa186/5760863 by guest on 01 M
arch 2020
 18 
 
11. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-
2015: the Global Burden of Disease Study 2015. The lancet HIV 2016; 3(8): e361-e87. 
12. De Francesco D, Wit FW, Burkle A, et al. Do people living with HIV experience greater age 
advancement than their HIV-negative counterparts? AIDS (London, England) 2019; 33(2): 
259-68. 
13. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic 
immune activation in chronic HIV infection. Nat Med 2006; 12(12): 1365-71. 
14. Christensen-Quick A, Massanella M, Frick A, et al. Subclinical Cytomegalovirus DNA Is 
Associated with CD4 T Cell Activation and Impaired CD8 T Cell CD107a Expression in 
People Living with HIV despite Early Antiretroviral Therapy. Journal of Virology 2019. 
15. Peterson I, Ming D, Kelly C, et al. Unstructured treatment interruption: an important risk 
factor for arterial stiffness in adult Malawian patients with antiretroviral treatment. AIDS 
(London, England) 2016; 30(15): 2373-8. 
16. Glennie SJ, Nyirenda M, Williams NA, Heyderman RS. Do multiple concurrent infections in 
African children cause irreversible immunological damage? Immunology 2012; 135(2): 125-
32. 
17. Mehraj V, Ramendra R, Isnard S, et al. Circulating (1-->3)-beta-D-Glucan is associated with 
immune activation during HIV infection. Clinical infectious diseases : an official publication 
of the Infectious Diseases Society of America 2019. 
18. Elliott AM, Mawa PA, Joseph S, et al. Associations between helminth infection and CD4+ T 
cell count, viral load and cytokine responses in HIV-1-infected Ugandan adults. Transactions 
of the Royal Society of Tropical Medicine and Hygiene 2003; 97(1): 103-8. 
19. Bourke CD, Gough EK, Pimundu G, et al. Cotrimoxazole reduces systemic inflammation in 
HIV infection by altering the gut microbiome and immune activation. Science translational 
medicine 2019; 11(486). 
20. Siika A, McCabe L, Bwakura-Dangarembizi M, et al. Late Presentation With HIV in Africa: 
Phenotypes, Risk, and Risk Stratification in the REALITY Trial. Clinical infectious diseases : 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa186/5760863 by guest on 01 M
arch 2020
 19 
 
an official publication of the Infectious Diseases Society of America 2018; 66(suppl_2): 
S140-S6. 
21. Rb-Silva R, Nobrega C, Azevedo C, et al. Thymic Function as a Predictor of Immune 
Recovery in Chronically HIV-Infected Patients Initiating Antiretroviral Therapy. Front 
Immunol 2019; 10: 25. 
22. Kelly C, Gaskell KM, Richardson M, Klein N, Garner P, MacPherson P. Discordant Immune 
Response with Antiretroviral Therapy in HIV-1: A Systematic Review of Clinical Outcomes. 
PLoS One 2016; 11(6): e0156099. 
23. Castillo-Mancilla JR, Morrow M, Boum Y, et al. Brief Report: Higher ART Adherence Is 
Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve 
Virologic Suppression. Journal of acquired immune deficiency syndromes (1999) 2018; 
77(5): 507-13. 
24. Leddy AM, Roque A, Sheira LA, et al. Food Insecurity Is Associated With Inflammation 
Among Women Living With HIV. J Infect Dis 2019; 219(3): 429-36. 
25. Mori M, Leitman E, Walker B, Ndung'u T, Carrington M, Goulder P. Impact of HLA Allele-
KIR Pairs on HIV Clinical Outcome in South Africa. J Infect Dis 2019; 219(9): 1456-63. 
26. Banchereau R, Hong S, Cantarel B, et al. Personalized Immunomonitoring Uncovers 
Molecular Networks that Stratify Lupus Patients. Cell 2016; 165(6): 1548-50. 
27. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J 
Respir Crit Care Med 2008; 178(3): 218-24. 
28. Taverner D, Paredes S, Ferré R, Masana L, Castro A, Vallvé J-C. Assessment of arterial 
stiffness variables in patients with rheumatoid arthritis: A mediation analysis. 
29. Laurent S, Alivon M, Beaussier H, Boutouyrie P. Aortic stiffness as a tissue biomarker for 
predicting future cardiovascular events in asymptomatic hypertensive subjects. Annals of 
medicine 2012; 44 Suppl 1: S93-7. 
30. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: 
methodological issues and clinical applications. European heart journal 2006; 27(21): 2588-
605. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa186/5760863 by guest on 01 M
arch 2020
 20 
 
31. Kooij KW, Schouten J, Wit FW, et al. Difference in Aortic Stiffness Between Treated 
Middle-Aged HIV Type 1-Infected and Uninfected Individuals Largely Explained by 
Traditional Cardiovascular Risk Factors, With an Additional Contribution of Prior Advanced 
Immunodeficiency. Journal of acquired immune deficiency syndromes (1999) 2016; 73(1): 
55-62. 
32. Ding FM, Li M, Yang X, et al. Accelerated Age-Related Arterial Stiffness in Systemic Lupus 
Erythematosus Patients. Journal of clinical rheumatology : practical reports on rheumatic & 
musculoskeletal diseases 2016; 22(8): 426-33. 
33. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation predicts carotid artery stiffness 
among HIV-infected women. Atherosclerosis 2011; 217(1): 207-13. 
34. Tann CJ, Nkurunziza P, Nakakeeto M, et al. Prevalence of bloodstream pathogens is higher in 
neonatal encephalopathy cases vs. controls using a novel panel of real-time PCR assays. PLoS 
One 2014; 9(5): e97259. 
35. Rousseeuw P. Silhouettes: A Graphical Aid to the Interpretation and Validation of Cluster 
Analysis. Journal of Computational and Applied Mathematics 1987; 20: 53-65. 
36. Troyanskaya O, Cantor M, Sherlock G, et al. Missing value estimation methods for DNA 
microarrays. Bioinformatics 2001; 17(6): 520-5. 
37. Wang R, Shlipak MG, Ix JH, et al. Association of Fibroblast Growth Factor-23 (FGF-23) 
With Incident Frailty in HIV-Infected and HIV-Uninfected Individuals. Journal of acquired 
immune deficiency syndromes (1999) 2019; 80(1): 118-25. 
38. Clayton KL, Collins DR, Lengieza J, et al. Resistance of HIV-infected macrophages to 
CD8(+) T lymphocyte-mediated killing drives activation of the immune system. Nature 
immunology 2018; 19(5): 475-86. 
39. Ostrowski SR, Gerstoft J, Pedersen BK, Ullum H. Impaired production of cytokines is an 
independent predictor of mortality in HIV-1-infected patients. AIDS (London, England) 
2003; 17(4): 521-30. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa186/5760863 by guest on 01 M
arch 2020
 21 
 
40. Shive CL, Mudd JC, Funderburg NT, et al. Inflammatory cytokines drive CD4+ T-cell 
cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV 
disease. J Infect Dis 2014; 210(4): 619-29. 
41. Hakim J, Musiime V, Szubert A, et al. Enhanced Prophylaxis plus Antiretroviral Therapy for 
Advanced HIV Infection in Africa. The New England journal of medicine 2017; 377(3): 233-
45. 
42. Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAART-induced HIV suppression 
on circulating markers of inflammation and immune activation. AIDS (London, England) 
2015; 29(4): 463-71. 
43. Fourie CM, Schutte AE, Smith W, Kruger A, van Rooyen JM. Endothelial activation and 
cardiometabolic profiles of treated and never-treated HIV infected Africans. Atherosclerosis 
2015; 240(1): 154-60. 
44. Siedner MJ, Kim JH, Nakku RS, et al. HIV infection and arterial stiffness among older-adults 
taking antiretroviral therapy in rural Uganda. AIDS (London, England) 2016; 30(4): 667-70. 
45. Scherzer R, Shah SJ, Secemsky E, et al. Association of Biomarker Clusters With Cardiac 
Phenotypes and Mortality in Patients With HIV Infection. Circulation Heart failure 2018; 
11(4): e004312. 
46. Hsue PY, Ribaudo HJ, Deeks SG, et al. Safety and Impact of Low-Dose Methotrexate on 
Endothelial Function and Inflammation in Individuals with Treated Human 
Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. Clinical infectious 
diseases : an official publication of the Infectious Diseases Society of America 2018. 
47. Coghill AE, Schenk JM, Mahkoul Z, Orem J, Phipps W, Casper C. Omega-3 decreases IL-6 
levels in HIV and human herpesvirus-8 coinfected patients in Uganda. AIDS (London, 
England) 2018; 32(4): 505-12. 
48. Dube MP, Chan ES, Lake JE, et al. A Randomized, Double-Blinded, Placebo-Controlled 
Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and 
Suppressed HIV Infection. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America 2018. 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa186/5760863 by guest on 01 M
arch 2020
 22 
 
49. Routy JP, Isnard S, Mehraj V, et al. Effect of metformin on the size of the HIV reservoir in 
non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol. 
BMJ open 2019; 9(4): e028444. 
50. Hunt PW, Martin JN, Sinclair E, et al. Valganciclovir reduces T cell activation in HIV-
infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect 
Dis 2011; 203(10): 1474-83. 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciaa186/5760863 by guest on 01 M
arch 2020
 23 
 
Tables 
Table 1. Clinical characteristics of Inflammatory clusters 
 
 
Cluster 1 (n=51) Cluster 2 (n=153) Cluster 3 (n=7) p value 
Median or 
frequency 
IQR or % Median or 
frequency 
IQR or % Median or 
frequency 
IQR or % 
Clinical 
characteristics 
Age (years) 38 31 – 44 36 31 – 43 40 31 - 43 0.77 
Systolic BP (mmHg) 124 109 – 132 119 108 – 128 128 106 – 129 0.47 
Diastolic BP 73 68 – 78 72 68 – 80 78 72 – 89 0.26 
Heart rate (bpm) 80 72 – 99 82 72 – 98 74 64 – 87 0.34 
Temperature (°C) 36.4 36. 0 – 36.8 36.4 36.0 – 36.9 36.5 36.0 – 36.9 0.88 
Haemoglobin (g/dL) 11.5 10.1 – 12.6 11.4 9.9 – 13.0 12.7 11.9 – 13.0 0.51 
Creatinine (µmol/L) 62 52 – 72 66 56 – 79 60 51 – 65 0.029 
Platelets (x10
9
/L) 215 172 – 325 240 189 – 332 216 144 – 435 0.34 
Nadir CD4 (cells/mm
3
) 42 19 – 65 41 19 – 62 17 11 – 44 0.44 
HIV viral load 
(copies/mL) 
117,000 46,000 – 
249,000 
111,000 39,000 – 
295,000 
210,000 86,000 – 
601,000 
0.51 
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Acute co-infection 11 22% 45 29% 1 14% 0.72 
CMV PCR positive 16 33% 43 28% 2 40% 0.90 
Death 0 0% 14 9% 0 0% 0.097 
Arterial stiffness Week 2 cfPWV (m/s) 7.5 7.4 – 7.6 7.3 7.2 – 7.4 6.6 6.3 – 6.8 0.041 
Week 12 PWV (m/s) 7.4 6.9 – 7.6 7.3 6.5 – 7.6 6.9 6.5 – 7.5 0.30 
Week 24 cfPWV (m/s) 7.3 6.5 – 7.5 7.1 6.5 - 7.4 6.8 6.3 - 7.5 0.76 
Week 44 cfPWV (m/s) 7.4 7.0 – 7.9 7.1 7.0 – 7.9 7.5 6.6 – 8.1 0.75 
Immune cell 
surface phenotype 
%CD4 Activation 86 76 – 90 68 54 – 76 69 50 – 96 <0.0001 
%CD4 Exhaustion 69 63 – 76 39 25 – 52 33 17 – 49 <0.0001 
%CD4 Senescence 18 9 – 29 14 8– 22 17 17 – 18 0.42 
%CD8 Activation 84 76– 90 72 59 – 86 83 65 – 96 <0.0001 
%CD8 Exhaustion 54 44 – 61 33 23 – 42 42 37 – 48 <0.0001 
%CD8 Senescence 51 43– 59 54 44 – 66 54 51 – 63 0.45 
%Intermediate 
Monocytes 
7.7 4.6 – 11.9 10.3 6.7 – 13.8 12.8 9.8 – 14.9 0.004 
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Table 2. Linear regression model showing the adjusted association between inflammatory cluster and arterial stiffness at 2 weeks post ART 
initiation 
 Fold change in cfPWV at 
baseline (m/s) 
95% Confidence Intervals P value 
Cluster 2* 0.91 0.83 1.01 0.08 
Cluster 3* 0.63 0.47 0.85 0.002 
Age (years) (per 10 years older) 1.18 1.12 1.23 <0.0001 
Female sex 1.00 0.91 1.10 0.96 
Systolic BP (mmHg) (per 10 mmHg higher) 1.03 1.00 1.06 0.07 
Diastolic BP (mmHg) (per 10 mmHg higher) 1.09 1.03 1.15 0.002 
Haemoglobin (g/dL) (per g/dL higher) 1.01 0.99 1.04 0.23 
*In comparison to cluster 1. cfPWV: carotid femoral Pulse Wave Velocity
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Table 3. Mixed model analysis showing the effect of inflammatory biomarker cluster on cfPWV slope over 42 weeks post ART initiation 
 
 Fold change in cfPWV  95% Confidence Interval p value 
Average effect of Time on cfPWV at 42 weeks post ART 0.94 0.90 0.98 0.007 
Average effect of Cluster on cfPWV at 42 weeks post ART  
Cluster 2 versus Cluster 1 0.95 0.85 1.05 0.30 
Cluster 3 versus Cluster 1  0.89 0.69 1.14 0.35 
Adjusted effect of cluster on rate of change in cfPWV over 42 weeks ART
a
  
Cluster 2 versus Cluster 1  0.99 0.86 1.14 0.91 
Cluster 3 versus Cluster 1 1.45 1.01 2.09 0.045 
Enrolment Age (per 10 year higher)  1.23 1.18 1.27 <0.0001 
Enrolment Diastolic BP (per 10 mmHg higher) 1.10 1.06 1.15 <0.0001 
Female sex (vs male) 0.97 0.90 1.04 0.36 
Enrolment Haemoglobin (g/dL) (per g/dL higher)  1.01 1.00 1.03 0.11 
Note: Adjusted for baseline cfPWV. 
a
Model showing effect of interaction between  cluster and time  on cfPWV over 42 weeks post ART initiation, adjusted 
for average effect of age, blood pressure, sex and haemoglobin. 
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Figure legends 
Figure 1. Identification of 3 distinct inflammatory biomarker clusters for 211 patients with HIV infection 
Note: clusters plotted against the first two principal components (percentage total variation explained) 
 
Figure 2. Heat map of 22 inflammatory biomarkers according to inflammatory cluster 
 
Figure 3. Change in cfPWV over 42 weeks of ART according to inflammatory cluster 
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Figure 1 
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Figure 2 
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Figure 3 
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